Search

Your search keyword '"Whisenant, Jennifer G"' showing total 225 results
Start Over Author "Whisenant, Jennifer G"
225 results on '"Whisenant, Jennifer G"'

1. A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

Author

Beckermann, Kathryn E., Bestvina, Christine M., El Osta, Badi, Sanborn, Rachel E., Borghaei, Hossein, Lammers, Philip Edward, Selvaggi, Giovanni, Whisenant, Jennifer G., Heimann-Nichols, Ellen, Berry, Lynne, Hsu, Chih-Yuan, Shyr, Yu, Horn, Leora, and Wakelee, Heather

Published
2024
Full Text
View/download PDF

2. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)

Author

Burns, Laura, Hsu, Chih-Yuan, Whisenant, Jennifer G., Marmarelis, Melina E., Presley, Carolyn J., Reckamp, Karen L., Khan, Hina, Jo Fidler, Mary, Bestvina, Christine M., Brahmer, Julie, Puri, Sonam, Patel, Jyoti D., Halmos, Balazs, Hirsch, Fred R., Liu, Stephen V., Costa, Daniel B., Goldberg, Sarah B., Feldman, Lawrence E., Mamdani, Hirva, Puc, Matthew, Mansfield, Aaron S., Islam, Nahida, Scilla, Katherine A., Garassino, Marina C., Horn, Leora, Peters, Solange, Wakelee, Heather A., Charlot, Marjory, and Tapan, Umit

Published
2023
Full Text
View/download PDF

3. Factors Affecting Image Quality and Lesion Evaluability in Breast Diffusion-weighted MRI: Observations from the ECOG-ACRIN Cancer Research Group Multisite Trial (A6702)

Author

Whisenant, Jennifer G, Romanoff, Justin, Rahbar, Habib, Kitsch, Averi E, Harvey, Sara M, Moy, Linda, DeMartini, Wendy B, Dogan, Basak E, Yang, Wei T, Wang, Lilian C, Joe, Bonnie N, Wilmes, Lisa J, Hylton, Nola M, Oh, Karen Y, Tudorica, Luminita A, Neal, Colleen H, Malyarenko, Dariya I, McDonald, Elizabeth S, Comstock, Christopher E, Yankeelov, Thomas E, Chenevert, Thomas L, and Partridge, Savannah C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Clinical Trials and Supportive Activities, Breast Cancer, Cancer, Biomedical Imaging, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, multicenter trial, breast magnetic resonance imaging, apparent diffusion coefficient, artifacts, diagnostic performance
Abstract

ObjectiveThe A6702 multisite trial confirmed that apparent diffusion coefficient (ADC) measures can improve breast MRI accuracy and reduce unnecessary biopsies, but also found that technical issues rendered many lesions non-evaluable on diffusion-weighted imaging (DWI). This secondary analysis investigated factors affecting lesion evaluability and impact on diagnostic performance.MethodsThe A6702 protocol was IRB-approved at 10 institutions; participants provided informed consent. In total, 103 women with 142 MRI-detected breast lesions (BI-RADS assessment category 3, 4, or 5) completed the study. DWI was acquired at 1.5T and 3T using a four b-value, echo-planar imaging sequence. Scans were reviewed for multiple quality factors (artifacts, signal-to-noise, misregistration, and fat suppression); lesions were considered non-evaluable if there was low confidence in ADC measurement. Associations of lesion evaluability with imaging and lesion characteristics were determined. Areas under the receiver operating characteristic curves (AUCs) were compared using bootstrapping.ResultsThirty percent (42/142) of lesions were non-evaluable on DWI; 23% (32/142) with image quality issues, 7% (10/142) with conspicuity and/or localization issues. Misregistration was the only factor associated with non-evaluability (P = 0.001). Smaller (≤10 mm) lesions were more commonly non-evaluable than larger lesions (p

Published
2021

4. Mean Apparent Diffusion Coefficient Is a Sufficient Conventional Diffusion-weighted MRI Metric to Improve Breast MRI Diagnostic Performance: Results from the ECOG-ACRIN Cancer Research Group A6702 Diffusion Imaging Trial

Author

McDonald, Elizabeth S, Romanoff, Justin, Rahbar, Habib, Kitsch, Averi E, Harvey, Sara M, Whisenant, Jennifer G, Yankeelov, Thomas E, Moy, Linda, DeMartini, Wendy B, Dogan, Basak E, Yang, Wei T, Wang, Lilian C, Joe, Bonnie N, Wilmes, Lisa J, Hylton, Nola M, Oh, Karen Y, Tudorica, Luminita A, Neal, Colleen H, Malyarenko, Dariya I, Comstock, Christopher E, Schnall, Mitchell D, Chenevert, Thomas L, and Partridge, Savannah C

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Clinical Research, Breast Cancer, Prevention, Cancer, Biomedical Imaging, Adult, Aged, Breast, Breast Neoplasms, Diagnosis, Differential, Diffusion Magnetic Resonance Imaging, Female, Humans, Middle Aged, Prospective Studies, Reproducibility of Results, Sensitivity and Specificity, Societies, Medical, Young Adult, Medical and Health Sciences, Nuclear Medicine & Medical Imaging, Clinical sciences
Abstract

Background The Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Cancer Research Group A6702 multicenter trial helped confirm the potential of diffusion-weighted MRI for improving differential diagnosis of suspicious breast abnormalities and reducing unnecessary biopsies. A prespecified secondary objective was to explore the relative value of different approaches for quantitative assessment of lesions at diffusion-weighted MRI. Purpose To determine whether alternate calculations of apparent diffusion coefficient (ADC) can help further improve diagnostic performance versus mean ADC values alone for analysis of suspicious breast lesions at MRI. Materials and Methods This prospective trial (ClinicalTrials.gov identifier: NCT02022579) enrolled consecutive women (from March 2014 to April 2015) with a Breast Imaging Reporting and Data System category of 3, 4, or 5 at breast MRI. All study participants underwent standardized diffusion-weighted MRI (b = 0, 100, 600, and 800 sec/mm2). Centralized ADC measures were performed, including manually drawn whole-lesion and hotspot regions of interest, histogram metrics, normalized ADC, and variable b-value combinations. Diagnostic performance was estimated by using the area under the receiver operating characteristic curve (AUC). Reduction in biopsy rate (maintaining 100% sensitivity) was estimated according to thresholds for each ADC metric. Results Among 107 enrolled women, 81 lesions with outcomes (28 malignant and 53 benign) in 67 women (median age, 49 years; interquartile range, 41-60 years) were analyzed. Among ADC metrics tested, none improved diagnostic performance versus standard mean ADC (AUC, 0.59-0.79 vs AUC, 0.75; P = .02-.84), and maximum ADC had worse performance (AUC, 0.52; P < .001). The 25th-percentile ADC metric provided the best performance (AUC, 0.79; 95% CI: 0.70, 0.88), and a threshold using median ADC provided the greatest reduction in biopsy rate of 23.9% (95% CI: 14.8, 32.9; 16 of 67 BI-RADS category 4 and 5 lesions). Nonzero minimum b value (100, 600, and 800 sec/mm2) did not improve the AUC (0.74; P = .28), and several combinations of two b values (0 and 600, 100 and 600, 0 and 800, and 100 and 800 sec/mm2; AUC, 0.73-0.76) provided results similar to those seen with calculations of four b values (AUC, 0.75; P = .17-.87). Conclusion Mean apparent diffusion coefficient calculated with a two-b-value acquisition is a simple and sufficient diffusion-weighted MRI metric to augment diagnostic performance of breast MRI compared with more complex approaches to apparent diffusion coefficient measurement. © RSNA, 2020 Online supplemental material is available for this article.

Published
2021

8. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

Author

Garassino, Marina Chiara, Whisenant, Jennifer G, Huang, Li-Ching, Trama, Annalisa, Torri, Valter, Agustoni, Francesco, Baena, Javier, Banna, Giuseppe, Berardi, Rossana, Bettini, Anna Cecilia, Bria, Emilio, Brighenti, Matteo, Cadranel, Jacques, De Toma, Alessandro, Chini, Claudio, Cortellini, Alessio, Felip, Enriqueta, Finocchiaro, Giovanna, Garrido, Pilar, Genova, Carlo, Giusti, Raffaele, Gregorc, Vanesa, Grossi, Francesco, Grosso, Federica, Intagliata, Salvatore, La Verde, Nicla, Liu, Stephen V, Mazieres, Julien, Mercadante, Edoardo, Michielin, Olivier, Minuti, Gabriele, Moro-Sibilot, Denis, Pasello, Giulia, Passaro, Antonio, Scotti, Vieri, Solli, Piergiorgio, Stroppa, Elisa, Tiseo, Marcello, Viscardi, Giuseppe, Voltolini, Luca, Wu, Yi-Long, Zai, Silvia, Pancaldi, Vera, Dingemans, Anne-Marie, Van Meerbeeck, Jan, Barlesi, Fabrice, Wakelee, Heather, Peters, Solange, and Horn, Leora

Published
2020
Full Text
View/download PDF

11. Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer

Author

Horn, Leora, Whisenant, Jennifer G., Wakelee, Heather, Reckamp, Karen L., Qiao, Huan, Leal, Ticiana A., Du, Liping, Hernandez, Jennifer, Huang, Vincent, Blumenschein, George R., Waqar, Saiama N., Patel, Sandip P., Nieva, Jorge, Oxnard, Geoffrey R., Sanborn, Rachel E., Shaffer, Tristan, Garg, Kavita, Holzhausen, Allison, Harrow, Kimberly, Liang, Chris, Lim, Lee P., Li, Mark, and Lovly, Christine M.

Published
2019
Full Text
View/download PDF

13. Identification and Characterization of Avoidable Hospital Admissions in Patients With Lung Cancer

Author

Lander, Eric M., primary, Li, Xuanyi, additional, Huang, Li-Ching, additional, Cass, Amanda S., additional, Iams, Wade T., additional, Skotte, Emily A., additional, Whisenant, Jennifer G., additional, Ramirez, Robert A., additional, York, Sally J., additional, Osterman, Travis J., additional, Lewis, Jennifer A., additional, Lovly, Christine M., additional, Shyr, Yu, additional, and Horn, Leora, additional

Published
2023
Full Text
View/download PDF

15. Quantitative imaging using MRI

Author

Hormuth, David A., primary, Virostko, John, additional, Stokes, Ashley, additional, Dula, Adrienne, additional, Sorace, Anna G., additional, Whisenant, Jennifer G., additional, Weis, Jared A., additional, Quarles, C. Chad, additional, Miga, Michael I., additional, and Yankeelov, Thomas E., additional

Published
2019
Full Text
View/download PDF

18. Supplemental Figure 1 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

19. Supplemental Table 1 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

20. Supplemental Table 2 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

21. Supplemental Table 3 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

22. Supplemental Figure 2 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

23. Supplemental Figure 3 from Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study

Author

Horn, Leora, primary, Infante, Jeffrey R., primary, Reckamp, Karen L., primary, Blumenschein, George R., primary, Leal, Ticiana A., primary, Waqar, Saiama N., primary, Gitlitz, Barbara J., primary, Sanborn, Rachel E., primary, Whisenant, Jennifer G., primary, Du, Liping, primary, Neal, Joel W., primary, Gockerman, Jon P., primary, Dukart, Gary, primary, Harrow, Kimberly, primary, Liang, Chris, primary, Gibbons, James J., primary, Holzhausen, Allison, primary, Lovly, Christine M., primary, and Wakelee, Heather A., primary

Published
2023
Full Text
View/download PDF

30. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis

Author

Bestvina, Christine M., primary, Whisenant, Jennifer G., additional, Torri, Valter, additional, Cortellini, Alessio, additional, Wakelee, Heather, additional, Peters, Solange, additional, Roca, Elisa, additional, De Toma, Alessandro, additional, Hirsch, Fred R., additional, Mamdani, Hirva, additional, Halmos, Balazs, additional, Arrieta, Oscar, additional, Metivier, Anne-Cecile, additional, Fidler, Mary J., additional, Rogado, Jacobo, additional, Presley, Carolyn J., additional, Mascaux, Celine, additional, Genova, Carlo, additional, Blaquier, Juan Bautista, additional, Addeo, Alfredo, additional, Finocchiaro, Giovanna, additional, Khan, Hina, additional, Mazieres, Julien, additional, Morgillo, Floriana, additional, Bar, Jair, additional, Aujayeb, Avinash, additional, Mountzios, Giannis, additional, Scotti, Vieri, additional, Grosso, Federica, additional, Geraedts, Erica, additional, Zhumagaliyeva, Ardak N., additional, Horn, Leora, additional, Garassino, Marina Chiara, additional, and Baena, Javier, additional

Published
2022
Full Text
View/download PDF

31. Characterization of avoidable hospital admissions in patients with lung cancer in the immunotherapy and targeted therapy era.

Author

Lander, Eric Michael, primary, Huang, Li-Ching, additional, Cass, Amanda, additional, Skotte, Emily A., additional, Whisenant, Jennifer G., additional, Iams, Wade Thomas, additional, Lovly, Christine M., additional, Osterman, Travis John, additional, Lewis, Jennifer A., additional, York, Sally J., additional, Shyr, Yu, additional, and Horn, Leora, additional

Published
2022
Full Text
View/download PDF

33. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry

Author

Whisenant, Jennifer G., primary, Baena, Javier, additional, Cortellini, Alessio, additional, Huang, Li-Ching, additional, Lo Russo, Giuseppe, additional, Porcu, Luca, additional, Wong, Selina K., additional, Bestvina, Christine M., additional, Hellmann, Matthew D., additional, Roca, Elisa, additional, Rizvi, Hira, additional, Monnet, Isabelle, additional, Boudjemaa, Amel, additional, Rogado, Jacobo, additional, Pasello, Giulia, additional, Leighl, Natasha B., additional, Arrieta, Oscar, additional, Aujayeb, Avinash, additional, Batra, Ullas, additional, Azzam, Ahmed Y., additional, Unk, Mojca, additional, Azab, Mohammed A., additional, Zhumagaliyeva, Ardak N., additional, Gomez-Martin, Carlos, additional, Blaquier, Juan B., additional, Geraedts, Erica, additional, Mountzios, Giannis, additional, Serrano-Montero, Gloria, additional, Reinmuth, Niels, additional, Coate, Linda, additional, Marmarelis, Melina, additional, Presley, Carolyn J., additional, Hirsch, Fred R., additional, Garrido, Pilar, additional, Khan, Hina, additional, Baggi, Alice, additional, Mascaux, Celine, additional, Halmos, Balazs, additional, Ceresoli, Giovanni L., additional, Fidler, Mary J., additional, Scotti, Vieri, additional, Métivier, Anne-Cécile, additional, Falchero, Lionel, additional, Felip, Enriqueta, additional, Genova, Carlo, additional, Mazieres, Julien, additional, Tapan, Umit, additional, Brahmer, Julie, additional, Bria, Emilio, additional, Puri, Sonam, additional, Popat, Sanjay, additional, Reckamp, Karen L., additional, Morgillo, Floriana, additional, Nadal, Ernest, additional, Mazzoni, Francesca, additional, Agustoni, Francesco, additional, Bar, Jair, additional, Grosso, Federica, additional, Avrillon, Virginie, additional, Patel, Jyoti D., additional, Gomes, Fabio, additional, Ibrahim, Ehab, additional, Trama, Annalisa, additional, Bettini, Anna C., additional, Barlesi, Fabrice, additional, Dingemans, Anne-Marie, additional, Wakelee, Heather, additional, Peters, Solange, additional, Horn, Leora, additional, Garassino, Marina Chiara, additional, and Torri, Valter, additional

Published
2022
Full Text
View/download PDF

35. A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry

Author

Whisenant, Jennifer G, Baena, Javier, Cortellini, Alessio, Huang, Li-Ching, Lo Russo, Giuseppe, Porcu, Luca, Wong, Selina K, Bestvina, Christine M, Hellmann, Matthew D, Roca, Elisa, Rizvi, Hira, Monnet, Isabelle, Boudjemaa, Amel, Rogado, Jacobo, Pasello, Giulia, Leighl, Natasha B, Arrieta, Oscar, Aujayeb, Avinash, Batra, Ullas, Azzam, Ahmed Y, Unk, Mojca, Azab, Mohammed A, Zhumagaliyeva, Ardak N, Gomez-Martin, Carlos, Blaquier, Juan B, Geraedts, Erica, Mountzios, Giannis, Serrano-Montero, Gloria, Reinmuth, Niels, Coate, Linda, Marmarelis, Melina, Presley, Carolyn J, Hirsch, Fred R, Garrido, Pilar, Khan, Hina, Baggi, Alice, Mascaux, Celine, Halmos, Balazs, Ceresoli, Giovanni L, Fidler, Mary J, Scotti, Vieri, Métivier, Anne-Cécile, Falchero, Lionel, Felip, Enriqueta, Genova, Carlo, Mazieres, Julien, Tapan, Umit, Brahmer, Julie, Bria, Emilio, Puri, Sonam, Popat, Sanjay, Reckamp, Karen L, Morgillo, Floriana, Nadal, Ernest, Mazzoni, Francesca, Agustoni, Francesco, Bar, Jair, Grosso, Federica, Avrillon, Virginie, Patel, Jyoti D, Gomes, Fabio, Ibrahim, Ehab, Trama, Annalisa, Bettini, Anna C, Barlesi, Fabrice, Dingemans, Anne-Marie, Wakelee, Heather, Peters, Solange, Horn, Leora, Garassino, Marina Chiara, and Torri, Valter

Subjects
TERAVOLT, Lung Neoplasms, thoracic, SARS-CoV-2, COVID-19, NSCLC, cancer, mortality, registry, Thoracic Neoplasms, Prognosis, C-Reactive Protein, COVID-19 Testing, Humans, Original Article, Registries, Retrospective Studies
Abstract

Patients with thoracic malignancies are at increased risk for mortality from coronavirus disease 2019 (COVID-19), and a large number of intertwined prognostic variables have been identified so far.Capitalizing data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, a global study created with the aim of describing the impact of COVID-19 in patients with thoracic malignancies, we used a clustering approach, a fast-backward step-down selection procedure, and a tree-based model to screen and optimize a broad panel of demographics and clinical COVID-19 and cancer characteristics.As of April 15, 2021, a total of 1491 consecutive eligible patients from 18 countries were included in the analysis. With a mean observation period of 42 days, 361 events were reported with an all-cause case fatality rate of 24.2%. The clustering procedure screened 73 covariates in 13 clusters. A further multivariable logistic regression for the association between clusters and death was performed, resulting in five clusters significantly associated with the outcome. The fast-backward step-down selection procedure then identified the following seven major determinants of death: Eastern Cooperative Oncology Group-performance status (ECOG-PS) (OR = 2.47, 1.87-3.26), neutrophil count (OR = 2.46, 1.76-3.44), serum procalcitonin (OR = 2.37, 1.64-3.43), development of pneumonia (OR = 1.95, 1.48-2.58), C-reactive protein (OR = 1.90, 1.43-2.51), tumor stage at COVID-19 diagnosis (OR = 1.97, 1.46-2.66), and age (OR = 1.71, 1.29-2.26). The receiver operating characteristic analysis for death of the selected model confirmed its diagnostic ability (area under the receiver operating curve = 0.78, 95% confidence interval: 0.75-0.81). The nomogram was able to classify the COVID-19 mortality in an interval ranging from 8% to 90%, and the tree-based model recognized ECOG-PS, neutrophil count, and c-reactive protein as the major determinants of prognosis.From 73 variables analyzed, seven major determinants of death have been identified. Poor ECOG-PS was found to have the strongest association with poor outcome from COVID-19. With our analysis, we provide clinicians with a definitive prognostication system to help determine the risk of mortality for patients with thoracic malignancies and COVID-19.

Published
2022

36. Palliative Care Exposure Relative to Predicted Risk of 6-Month Mortality in Hospitalized Adults

Author

Agarwal, Rajiv, Domenico, Henry J., Balla, Sreenivasa R., Byrne, Daniel W., Whisenant, Jennifer G., Woods, Marcella C., Martin, Barbara J., Karlekar, Mohana B., and Bennett, Marc L.

Subjects
Adult, Cohort Studies, Hospitalization, Machine Learning, Male, Palliative Care, Humans, Female, Middle Aged, Risk Assessment, Article, Retrospective Studies
Abstract

CONTEXT: The optimal strategy for implementing mortality-predicting algorithms to facilitate clinical care, prognostic discussions, and palliative care interventions remains unknown. OBJECTIVES: To develop and validate a real-time predictive model for 180-day mortality using routinely available clinical and laboratory admission data and determine if palliative care exposure varies with predicted mortality risk. METHODS: Adult admissions between 10/1/2013 and 10/1/2017 were included for the model derivation. A separate cohort was collected between 1/1/2018 and 7/31/2020 for validation. Patients were followed for 180 days from discharge, and logistic regression with selected variables was used to estimate patients’ risk for mortality. RESULTS: In the model derivation cohort, 7963 events of 180-day mortality (4.5% event rate) were observed. Median age was 53.0 (IQR 24.0–66.0) with 92,734 females (52.5%). Variables with strongest association with 180-day mortality included: Braden Score (OR 0.83; 95% CI 0.82–0.84); admission Do Not Resuscitate orders (OR 2.61; 95% CI 2.43–2.79); admission service and admission status. The model yielded excellent discriminatory ability in both the derivation (c-statistic 0.873; 95% CI 0.870–0.877; Brier score 0.04) and validation cohorts (c-statistic 0.844; 95% CI 0.840–0.847; Brier score 0.072). Inpatient palliative care consultations increased from 3% of minimal-risk encounters to 41% of high-risk encounters (p

Published
2022

37. COVID-19 and cancer: A registry-based pandemic response

Author

Desai, Aakash, Mohammed, Turab J., Duma, Narjust, Garassino, Marina C., Hicks, Lisa K., Kuderer, Nicole M., Lyman, Gary H., Mishra, Sanjay, Pinato, David J., Rini, Brian I., Peters, Solange, Warner, Jeremy L., Whisenant, Jennifer G., Wood, William A., and Thompson, Michael A.

Subjects
Neoplasms, COVID-19, Humans, Registries, Pandemics, Article
Abstract

The COVID-19 pandemic has had consequences for patients with cancer worldwide and has been associated with delays in diagnosis, interruption of treatment and follow-up care, and increases in overall infection rates and premature mortality.Despite the challenges experienced during the pandemic, the global oncology community has responded with an unprecedented level of investigation, collaboration, and technological innovation through the rapid development of COVID-19 registries that have allowed an increased understanding of the natural history, risk factors, and outcomes of patients with cancer who are diagnosed with COVID-19. This review describes 14 major registries comprising more than 28 500 patients with cancer and COVID-19; these ongoing registry efforts have provided an improved understanding of the impact and outcomes of COVID-19 among patients with cancer.An initiative is needed to promote active collaboration between different registries to improve the quality and consistency of information. Well-designed prospective and randomized clinical trials are needed to collect high-level evidence to guide long-term epidemiologic, behavioral, and clinical decision-making for this and future pandemics.

Published
2021

38. COVID-19 and Cancer

Author

Desai, Aakash, primary, Mohammed, Turab J., additional, Duma, Narjust, additional, Garassino, Marina C., additional, Hicks, Lisa K., additional, Kuderer, Nicole M., additional, Lyman, Gary H., additional, Mishra, Sanjay, additional, Pinato, David J., additional, Rini, Brian I., additional, Peters, Solange, additional, Warner, Jeremy L., additional, Whisenant, Jennifer G., additional, Wood, William A., additional, and Thompson, Michael A., additional

Published
2021
Full Text
View/download PDF

39. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

Author

Horn, Leora, primary, Wang, Ziping, additional, Wu, Gang, additional, Poddubskaya, Elena, additional, Mok, Tony, additional, Reck, Martin, additional, Wakelee, Heather, additional, Chiappori, Alberto A., additional, Lee, Dae Ho, additional, Breder, Valeriy, additional, Orlov, Sergey, additional, Cicin, Irfan, additional, Cheng, Ying, additional, Liu, Yunpeng, additional, Fan, Yun, additional, Whisenant, Jennifer G., additional, Zhou, Yi, additional, Oertel, Vance, additional, Harrow, Kim, additional, Liang, Chris, additional, Mao, Li, additional, Selvaggi, Giovanni, additional, and Wu, Yi-Long, additional

Published
2021
Full Text
View/download PDF

41. Additional file 1 of Enhancing Cancer care of rural dwellers through telehealth and engagement (ENCORE): protocol to evaluate effectiveness of a multi-level telehealth-based intervention to improve rural cancer care delivery

Author

Pal, Tuya, Hull, Pamela C., Koyama, Tatsuki, Lammers, Phillip, Martinez, Denise, McArthy, Jacob, Schremp, Emma, Tezak, Ann, Washburn, Anne, Whisenant, Jennifer G., and Friedman, Debra L.

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2021
Full Text
View/download PDF

42. Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts.

Author

Wong, Selina K., primary, Whisenant, Jennifer G., additional, Bestvina, Christine M., additional, Berry, Lynne D, additional, Owonikoko, Taofeek K., additional, Sanborn, Rachel E., additional, Lammers, Philip Edward, additional, El Osta, Badi Edmond, additional, Ramalingam, Suresh S., additional, Carlisle, Jennifer W, additional, Steuer, Conor Ernst, additional, Borghaei, Hossein, additional, Selvaggi, Giovanni, additional, Shyr, Yu, additional, Wakelee, Heather A., additional, Horn, Leora, additional, and Beckermann, Katy, additional

Published
2021
Full Text
View/download PDF

43. A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naive metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176).

Author

Roth, Marc Thomas, primary, Catalano, Paul J., additional, Ciombor, Kristen Keon, additional, Benson, Al Bowen, additional, Yao, Xin, additional, Yaeger, Rona, additional, Salem, Mohamed E., additional, Morris, Van K., additional, Henry, David H., additional, Whisenant, Jennifer G., additional, O'Dwyer, Peter J., additional, and Eng, Cathy, additional

Published
2021
Full Text
View/download PDF

44. First-in-Human PET Imaging and Estimated Radiation Dosimetry of l-[5-11C]-Glutamine in Patients with Metastatic Colorectal Cancer

Author

Cohen, Allison S., primary, Grudzinski, Joe, additional, Smith, Gary T., additional, Peterson, Todd E., additional, Whisenant, Jennifer G., additional, Hickman, Tiffany L., additional, Ciombor, Kristen K., additional, Cardin, Dana, additional, Eng, Cathy, additional, Goff, Laura W., additional, Das, Satya, additional, Coffey, Robert J., additional, Berlin, Jordan D., additional, and Manning, H. Charles, additional

Published
2021
Full Text
View/download PDF

45. Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies

Author

Cortellini, Alessio, Dingemans, Anne-Marie C., Arrieta, Oscar, Baena, Javier, Brighenti, Matteo, Felip, Enriqueta, Garassino, Marina Chiara, Garrido, Pilar, Genova, Carlo, Grosso, Federica, Horn, Leora, Huang, Li-Ching, Meerbeeck, Jan, Peters, Solange, Nadal, Ernest, Rogado, Jacobo, Shyr, Yu, Tiseo, Marcello, Torri, Valter, Trama, Annalisa, Wakelee, Heather, Whisenant, Jennifer G., Viscardi, Giuseppe, Barlesi, Fabrice, Sanjay Popat, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy

Published
2020

46. TERAVOLT: Thoracic Cancers International COVID-19 Collaboration Comment

Author

Whisenant, Jennifer G., Trama, Annalisa, Torri, Valter, De Toma, Alessandro, Viscardi, Giuseppe, Cortellini, Alessio, Michielin, Olivier, Barlesi, Fabrice, Dingemans, Anne-Marie C., van Meerbeeck, Jan, Pancaldi, Vera, Soo, Ross A., Leighl, Natasha B., Peters, Solange, Wakelee, Heather, Garassino, Marina Chiara, Horn, Leora, and Pulmonary Medicine

Subjects
SDG 3 - Good Health and Well-being, Human medicine, Biology
Abstract

Prior publications on small subsets of cancer patients infected with SARS CoV-2 have shown an increased risk of mortality compared to the general population. Furthermore, patients with thoracic malignancies are thought to be at particularly high risk given their older age, smoking habits, and pre-existing cardio-pulmonary comorbidities. For this reason, physicians around the world have formed TERAVOLT, a global consortium dedicated to understanding the impact of COVID-19 on patients with thoracic malignancies.

Published
2020

47. Factors Affecting Image Quality and Lesion Evaluability in Breast Diffusion-weighted MRI: Observations from the ECOG-ACRIN Cancer Research Group Multisite Trial (A6702)

Author

Whisenant, Jennifer G, primary, Romanoff, Justin, additional, Rahbar, Habib, additional, Kitsch, Averi E, additional, Harvey, Sara M, additional, Moy, Linda, additional, DeMartini, Wendy B, additional, Dogan, Basak E, additional, Yang, Wei T, additional, Wang, Lilian C, additional, Joe, Bonnie N, additional, Wilmes, Lisa J, additional, Hylton, Nola M, additional, Oh, Karen Y, additional, Tudorica, Luminita A, additional, Neal, Colleen H, additional, Malyarenko, Dariya I, additional, McDonald, Elizabeth S, additional, Comstock, Christopher E, additional, Yankeelov, Thomas E, additional, Chenevert, Thomas L, additional, and Partridge, Savannah C, additional

Published
2020
Full Text
View/download PDF

50. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma

Author

Wood, Christopher G., primary, Ferguson, James E., additional, Parker, Joel S., additional, Moore, Dominic T., additional, Whisenant, Jennifer G., additional, Maygarden, Susan J., additional, Wallen, Eric M., additional, Kim, William Y., additional, Milowsky, Mathew I., additional, Beckermann, Kathryn E., additional, Davis, Nancy B., additional, Haake, Scott M., additional, Karam, Jose A., additional, Bortone, Dante S., additional, Vincent, Benjamin G., additional, Powles, Thomas, additional, and Rathmell, W. Kimryn, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results